Máximo Fraga

2.6k total citations
81 papers, 1.8k citations indexed

About

Máximo Fraga is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Máximo Fraga has authored 81 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 30 papers in Molecular Biology and 27 papers in Pathology and Forensic Medicine. Recurrent topics in Máximo Fraga's work include Lymphoma Diagnosis and Treatment (25 papers), Viral-associated cancers and disorders (11 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). Máximo Fraga is often cited by papers focused on Lymphoma Diagnosis and Treatment (25 papers), Viral-associated cancers and disorders (11 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). Máximo Fraga collaborates with scholars based in Spain, United States and France. Máximo Fraga's co-authors include Jerónimo Forteza, Tomás García‐Caballero, A. Beiras, Miguel Á. Piris, Rosalı́a Gallego, José A. Costoya, Márcio Diniz Freitas, Luı́s Monteiro, Benoı̂t Viollet and Marc Foretz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Máximo Fraga

79 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Máximo Fraga Spain 25 701 653 505 248 222 81 1.8k
Endi Wang United States 24 801 1.1× 546 0.8× 557 1.1× 440 1.8× 335 1.5× 127 2.0k
Nikolaos E. Bechrakis Germany 32 496 0.7× 793 1.2× 764 1.5× 164 0.7× 515 2.3× 220 3.5k
Naoyoshi Mori Japan 25 1.0k 1.5× 650 1.0× 500 1.0× 334 1.3× 453 2.0× 111 2.2k
Maria Grazia Tibiletti Italy 29 810 1.2× 812 1.2× 838 1.7× 255 1.0× 85 0.4× 93 2.3k
Suzanne Jordan United Kingdom 22 345 0.5× 576 0.9× 727 1.4× 258 1.0× 128 0.6× 32 2.3k
D C Brown United Kingdom 17 345 0.5× 550 0.8× 620 1.2× 142 0.6× 85 0.4× 31 2.0k
Kazuhiro Nishii Japan 29 588 0.8× 547 0.8× 965 1.9× 320 1.3× 97 0.4× 105 2.6k
Lisa Ma United States 23 470 0.7× 567 0.9× 493 1.0× 701 2.8× 45 0.2× 40 2.1k
Jodi M. Carter United States 28 409 0.6× 636 1.0× 578 1.1× 74 0.3× 157 0.7× 129 2.4k
Hormoz Ehya United States 25 395 0.6× 592 0.9× 423 0.8× 102 0.4× 77 0.3× 82 1.9k

Countries citing papers authored by Máximo Fraga

Since Specialization
Citations

This map shows the geographic impact of Máximo Fraga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Máximo Fraga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Máximo Fraga more than expected).

Fields of papers citing papers by Máximo Fraga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Máximo Fraga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Máximo Fraga. The network helps show where Máximo Fraga may publish in the future.

Co-authorship network of co-authors of Máximo Fraga

This figure shows the co-authorship network connecting the top 25 collaborators of Máximo Fraga. A scholar is included among the top collaborators of Máximo Fraga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Máximo Fraga. Máximo Fraga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Orgueira, Adrián Mosquera, et al.. (2023). The implication of next-generation sequencing in the diagnosis and clinical management of non-Hodgkin lymphomas. Frontiers in Oncology. 13. 1275327–1275327. 1 indexed citations
2.
Gómez‐Carballa, Alberto, María José Currás-Tuala, Sara Pischedda, et al.. (2023). Multi-tissue transcriptomics of a unique monozygotic discordant twin case of severe progressive osseous heteroplasia. Genes & Diseases. 11(3). 100981–100981. 1 indexed citations
3.
Iglesias, Pablo, et al.. (2023). A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism. International Journal of Molecular Sciences. 24(10). 8849–8849.
4.
Martı́n, Alejandro, Socorro Marıá Rodríguez-Pinilla, Eva Domingo‐Doménech, et al.. (2023). Peripheral T‐cell lymphoma with a T follicular‐helper phenotype: A different entity? Results of the Spanish Real‐T study. British Journal of Haematology. 203(2). 182–193. 3 indexed citations
5.
Iglesias, Pablo, et al.. (2020). PARP1 Deficiency Reduces Tumour Growth by Decreasing E2F1 Hyperactivation: A Novel Mechanism in the Treatment of Cancer. Cancers. 12(10). 2907–2907. 8 indexed citations
6.
Santamarina‐Ojeda, Pablo, et al.. (2019). Abstracts from the 51st European Society of Human Genetics Conference: Oral Presentations. European Journal of Human Genetics. 27(S1). 748–869. 1 indexed citations
7.
Raya, José María, Santiago Montes‐Moreno, Agustín Acevedo, et al.. (2014). Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report. Journal of Clinical Pathology. 67(7). 620–625. 9 indexed citations
8.
García, Marcos Ríos, Marc Foretz, Benoı̂t Viollet, et al.. (2013). AMPK Activation by Oncogenesis Is Required to Maintain Cancer Cell Proliferation in Astrocytic Tumors. Cancer Research. 73(8). 2628–2638. 104 indexed citations
9.
Lamant, Laurence, Keith McCarthy, Emanuele S. G. d'Amore, et al.. (2011). Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study. Journal of Clinical Oncology. 29(35). 4669–4676. 98 indexed citations
10.
Pintos, E., et al.. (2010). Gastrointestinal stromal tumors (GISTs) of the colon. Revista Española de Enfermedades Digestivas. 102(6). 388–90. 5 indexed citations
11.
López, José Ramón Antúnez, et al.. (2009). Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis.. PubMed. 24(6). 675–82. 9 indexed citations
12.
Brea, David, Tomás Sobrino, Miguel Blanco, et al.. (2008). Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnosis confirmation. Atherosclerosis. 205(2). 561–567. 49 indexed citations
13.
Tojo, Marta, et al.. (2008). Looking for Ferns: Optimization of Digestion Pretreatment in Fluorescence In Situ Hybridization (FISH) Technique on Paraffin-embedded Tissues. Diagnostic Molecular Pathology. 17(1). 59–63. 3 indexed citations
14.
Richards, Michael, Carmen Altisent, Angelika Bátorová, et al.. (2007). Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia. 13(5). 473–479. 54 indexed citations
15.
16.
García‐Caballero, Tomás, et al.. (2006). HER-2 status determination in breast carcinomas. A practical approach.. PubMed. 21(3). 227–36. 11 indexed citations
17.
Sáez-Castillo, Antonio José, María-Jesús Artiga, Alberto Pérez‐Rosado, et al.. (2004). Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma. American Journal Of Pathology. 164(2). 613–622. 73 indexed citations
18.
19.
Abdulkader, Ihab, José Cameselle‐Teijeiro, Francisco Gudé, et al.. (2002). Predictors of malignant behaviour in gastrointestinal stromal tumours: a clinicopathological study of 34 cases. The European Journal of Surgery. 168(5). 288–296. 10 indexed citations
20.
Abdulkader, Ihab, José Cameselle‐Teijeiro, Máximo Fraga, et al.. (1999). Primary anaplastic large cell lymphoma of the central nervous system. Human Pathology. 30(8). 978–981. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Endi Wang Breakdown of academic impact, for papers by Nikolaos E. Bechrakis Breakdown of academic impact, for papers by Naoyoshi Mori Breakdown of academic impact, for papers by Maria Grazia Tibiletti Breakdown of academic impact, for papers by Suzanne Jordan Breakdown of academic impact, for papers by D C Brown Breakdown of academic impact, for papers by Kazuhiro Nishii Breakdown of academic impact, for papers by Lisa Ma Breakdown of academic impact, for papers by Jodi M. Carter Breakdown of academic impact, for papers by Hormoz Ehya
Rankless by CCL
2026